Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 15, 2007

Abeille Stands to Earn $21M in Deal with SymBio

  • Abeille Pharmaceuticals and SymBio Pharmaceuticals will together develop and sell Abeille's transdermal patch for emesis, in Japan, China, Korea, Taiwan, and Singapore.

    AB-1001, is a transdermal patch for chemotherapy-induced nausea and vomiting. It is designed to deliver a commercially available 5HT3-antagonist through the skin for a continuous period of up to five days. Abeille intends to initiate a Phase III trial of AB-1001 in the second quarter of 2007.

    SymBio will pay Abeille an upfront licensing fee and milestone-based payments, which could total up to $21 million. The agreement also calls for double-digit royalty payments on commercial sales.

    Abeille also granted SymBio the right of first refusal on Abeille's next product in the field.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »